WilmerHale represented the underwriters in the follow-on public offering of 12,466,600 shares of common stock, reflecting the full exercise of the underwriters’ option to purchase 1,800,000 additional shares of common stock, and 20,000 shares of Series B non-voting convertible preferred stock (“Series B Preferred Stock”) of Viridian Therapeutics, Inc., a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases. The shares of common stock were issued at a public offering price of $18.75 per share. The Series B Preferred Stock had a public offering price of $1,250.06250 per share. Aggregate gross proceeds to Viridian were approximately $258.8 million, before deducting underwriting discounts, commissions and offering expenses payable by Viridian. The offering priced on September 11, 2024 and closed on September 13, 2024.

The WilmerHale team representing the underwriters consisted of Lisa Firenze, Molly Fox, Ryan Brewer and Kevin Cheng, with assistance from Barish Ozdamar, with respect to intellectual property matters, and Meghan Walsh, with respect to tax matters.